

# Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults

NCT04477681

---

**Status** RECRUITING  
**Sponsor** Gustave Roussy, Cancer Campus, Grand Paris  
**Enrollment** 1,150 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Age d 25 years old at the time of inclusion in the study
  - Patient with a pediatric tumor or leukemia in therapeutic failure or relapse without standard therapeutic options. Exceptionally, patients on the first line of treatment without standard therapeutic options may also be included (eg g: inoperable plexiform neurofibroma and MEK inhibitors, childhood fibrosarcoma and NTRK inhibitors).
  - Patient not eligible for an early phase clinical trial open to inclusion on French territory or refusal of inclusion
  - Patient treated with a new drug discussed at a RCPPI as part of a compassionate use issued by the ANSM or an off-label prescription of a drug of interest already authorized in adults.
  - Patients treated in one of the SFCE centers authorized to prescribe chemotherapy
- ... and 1 more (see full listing online)

### Exclusion (3)

- Patient included in an early phase clinical trial open to inclusions on French territory.
- Oral refusal to participate by the patient or their legal representatives, in reading the information note specific to the study
- Patient under guardianship or curatorship, deprived of liberty or in the impossibility of expressing opposition to participating in the study

## Locations (32 total)

---

Gustave Roussy, Villejuif, Val de Marne, France  
CHU Amiens, Amiens, France  
CHU Angers, Angers, France  
... and 29 more locations